FDA Approves IND for Phase 3 Trial of iSCIB1+ in Melanoma
Episode Summary
FDA approval of a phase 3 trial for the iSCIB1+ melanoma vaccine advances personalized cancer treatment, offering potential survival benefits for patients with advanced disease.